Tokyo, Aug. 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062515) titled 'Study on the Effects of Human Sweat on the Skin' on Aug. 7.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - ROHTO Pharmaceutical Co., Ltd.

Condition: Condition - Healthy subjects Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To explore the effects of sweat on the skin Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Participants will enter a controlled environmental chamber. Sweating will be induced by stepping in place at a rhythm.

Eligibility: Age-lower limit - 18 years-old

Gender - Male and Female Key inclusion criteria - -Healthy adults aged 18 years or older and younger than 65 years at the time of informed consent. -Individuals who experience sufficient sweating during summer or under hot and humid conditions. -Individuals who have received an adequate explanation of the purpose and procedures of the study, have the capacity to provide consent, fully understand the study, voluntarily agree to participate, and provide written informed consent. Key exclusion criteria - -Individuals who are currently receiving, or have received within the past month, pharmacological treatment for any disease, except for occasional medication for conditions such as headache or common cold. -Individuals with a current or past history of psychiatric disorders, sleep disorders, hypertension, diabetes mellitus, dyslipidemia, or other serious diseases. -Individuals with a current or past history of serious hepatic, renal, cardiac, pulmonary, hematological, or other disorders. -Individuals who have previously sought medical attention or received treatment for heatstroke or suspected heatstroke. -Individuals who currently have, or have had within the past month, a disease that may affect sweating, thermoregulation, hemodynamics, fluid/electrolyte balance, or level of consciousness, or who are receiving pharmacological treatment for such a condition. -Individuals who have experienced fever, diarrhea, vomiting, severe fatigue, inadequate food intake, inadequate fluid intake, heatstroke-like symptoms, or symptoms suggestive of infection within one week prior to the study visit. -Individuals who are pregnant or breastfeeding at the time of informed consent, or who wish to become pregnant during the study period. -Individuals who have participated in another human study involving cosmetics, foods, pharmaceuticals, quasi-drugs, medical devices, or other interventions within the previous four weeks, or who plan to participate in another human study during the scheduled study period. -Individuals with bleeding wounds, infectious skin diseases, severe acne, or other facial conditions considered likely to affect the quality or safety of sweat samples. -Individuals otherwise considered unsuitable for participation by the principal investigator physician or sub-investigator physician. Target Size - 6

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 07 Month 22 Day Date of IRB - 2026 Year 08 Month 06 Day Anticipated trial start date - 2026 Year 08 Month 24 Day Last follow-up date - 2026 Year 08 Month 24 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071552

Disclaimer: Curated by HT Syndication.